Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.56 |
| ▸ | PPARD | Q03181 | 8/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835765 | 0.89 | FFAR1 (0.71) | FFAR1PPARDPPARAPPARGFFAR4 | |
| SCHEMBL12571007 | 0.84 | FFAR1 (0.78) | FFAR1FFAR4 | |
| SCHEMBL1549560 | 0.84 | PPARD (0.54) | FFAR1PPARDPPARAPPARGFFAR4 | |
| SCHEMBL5860709 | 0.82 | PPARD (0.59) | FFAR1PPARDPPARAPPARGFFAR4 | |
| SCHEMBL1746661 | 0.80 | FFAR1 (0.68) | FFAR1PPARDPPARGFFAR4 | |
| SCHEMBL1746560 | 0.79 | FFAR1 (0.67) | FFAR1PPARDFFAR4 | |
| SCHEMBL1745038 | 0.79 | FFAR1 (0.79) | FFAR1FFAR4 | |
| SCHEMBL1745405 | 0.78 | FFAR1 (0.83) | FFAR1FFAR4 | |
| SCHEMBL1745469 | 0.78 | FFAR1 (0.60) | FFAR1PPARDPPARAPPARGFFAR4 | |
| SCHEMBL16354320 | 0.78 | FFAR1 (0.65) | FFAR1PPARDPPARAPPARGFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338960-B2 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338960-B2 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338960-B2 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1513526-B1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060089394-A1 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2006-04-27 | — | — | US | disclosed |
| EP-1513526-A1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000315-A1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089394-A1 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators | LIPA, PNLIP, CEL | FFAR1 22/4885PPARD 83/4885PPARA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.